Search

MSK researchers have found mutations that arise in embryos can convey a risk of cancer that’s similar to what’s seen in people with inherited cancer mutations.

… Wednesday, January 5, 2022 The underlying genetic causes of cancer have traditionally been put into one of two categories: Tumors are caused either by somatic mutations, which arise by chance over the course of a person’s life, or by germline mutations, which are inherited at birth from a parent and

Learn more from Andrea Cercek about a new study showing that colorectal cancer rates are increasing in younger people.

… Tuesday, February 28, 2017 Summary MSK expert Andrea Cercek discusses findings from a new study showing rising colorectal cancer rates among people in their 20s and 30s. Though the overall incidence of colorectal cancer has been on the decline in the US for years, it is increasing among individuals in

Read about a new CAR T cell therapy now approved for marginal zone lymphoma (MZL).

… Friday, December 12, 2025 Marginal zone lymphoma is a slow-growing, rare form of  non-Hodgkin lymphoma that usually responds well to initial therapies. But in some patients, the disease keeps returning despite multiple treatments. Now the U.S. Food and Drug Administration (FDA) has approved a new therapy

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.

… Monday, October 7, 2019 Jaap-Jan “J. J.” Boelens joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service. Some of our MSK Kids patients asked him the questions they were most curious about. You’re a new doctor here at MSK Kids. Where did you come from? — James, 4 I

— Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest cavity — namely malignant pleural mesothelioma but also metastatic lung and breast cancer. The results from a phase I clinical trial were presented as part of the press program at the American Association for Cancer Research (AACR) Annual Meeting 2019. The findings showed tumor reduction in patients who participated in the study and no evidence of toxicity.

… Sunday, March 31, 2019 Researchers from Memorial Sloan Kettering Cancer Center (MSK) have shown early promising results in using a chimeric antigen receptor (CAR) T cell therapy that targets the protein mesothelin, which is expressed on the surface of cancer cells in patients with diseases of the chest

The U.S. Food and Drug Administration (FDA) has granted full approval to the drug tarlatamab, a bispecific T cell engager, for small cell lung cancer, based on results from a phase 3 clinical trial led by Dr. Charles Rudin at MSK.

… Thursday, November 20, 2025 On November 19, 2025, the U.S. Food and Drug Administration (FDA)  granted full approval  to the targeted immunotherapy drug  tarlatamab (Imdelltra ® )  for treating adults with advanced small cell lung cancer (SCLC) that has spread after platinum-based chemotherapy. The approval

In a plenary presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, Dr. Dana Pe’er highlighted three recent research collaborations between her lab and other labs at MSK that have shed new light on the ability of cancer cells to adapt and spread.

… Tuesday, April 9, 2024 About 90% of deaths from cancer are a result of metastasis — that is, from cancer’s ability to spread from an initial primary tumor to seed new tumors throughout the body, often in the lungs, liver, and brain. And metastasis relies on cancer cells’ ability to adapt to different

The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a 468-gene oncopanel intended to detect gene mutations and other critical genetic aberrations in both rare and common cancers.

… Wednesday, November 15, 2017 The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT ™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of

For the first time, a targeted drug is showing promise at treating non-small cell lung cancer caused by a mutation called KRAS-G12D.

… Sunday, April 27, 2025 For decades, cancers with mutations in the gene  KRAS (KAY-ras) were considered “undruggable.”  KRAS  mutations are found in more than 20% of cancers. They are most common in  lung cancer ,  pancreatic cancer , and  colorectal cancer . Nearly four years ago, the first drug was

Por primera vez, un fármaco dirigido está mostrando resultados prometedores en el tratamiento del cáncer pulmonar de células no pequeñas causado por una mutación llamada KRAS-G12D.

… Sunday, April 27, 2025 Durante décadas, los casos de cáncer con mutaciones en el gen  KRAS  se consideraron “no tratables con fármacos”. Las mutaciones en KRAS  se encuentran presentes en más del 20 % de los casos de cáncer. Son más comunes en el  cáncer pulmonar ,  el cáncer de páncreas y el  cáncer